Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) CFO Edward H. Myles sold 9,458 shares of the firm’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $8.98, for a total transaction of $84,932.84. Following the transaction, the chief financial officer now owns 201,518 shares of the company’s stock, valued at $1,809,631.64. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Scholar Rock Stock Down 3.3 %
Shares of SRRK stock opened at $8.49 on Wednesday. The company has a quick ratio of 6.58, a current ratio of 6.58 and a debt-to-equity ratio of 0.24. Scholar Rock Holding Co. has a fifty-two week low of $5.93 and a fifty-two week high of $21.17. The firm’s 50 day moving average price is $12.35 and its two-hundred day moving average price is $14.90.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.11). During the same quarter last year, the business posted ($0.46) EPS. Research analysts predict that Scholar Rock Holding Co. will post -2.4 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Scholar Rock
Analyst Upgrades and Downgrades
SRRK has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Scholar Rock in a report on Tuesday, June 4th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Scholar Rock in a research note on Tuesday, May 7th. Truist Financial reissued a “buy” rating and set a $20.00 price target on shares of Scholar Rock in a research note on Wednesday, April 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $28.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 26th. Finally, BMO Capital Markets raised their price target on Scholar Rock from $29.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday, June 13th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $26.00.
Get Our Latest Research Report on Scholar Rock
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Featured Stories
- Five stocks we like better than Scholar Rock
- Investing In Automotive Stocks
- Occidental Stock: Buffett’s 9-Day Buying Spree Lifts Stake to 29%
- Why is the Ex-Dividend Date Significant to Investors?
- 3M Stock: Invest Now for Unmatched Quality and Growth Potential
- What is a Bond Market Holiday? How to Invest and Trade
- Super Micro AI Stock: Should You Invest After a 275% Increase?
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.